---
figid: PMC10851565__12964_2023_1433_Fig2_HTML
figtitle: 'Interplay between proteasome inhibitors and NFKB pathway in leukemia and
  lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors'
organisms:
- NA
organisms_ner:
- NA
pmcid: PMC10851565
filename: 12964_2023_1433_Fig2_HTML.jpg
figlink: /pmc/articles/PMC10851565/figure/F2
number: F2
caption: Overview on agents targeting different parts of proteasome-mediated degradation
  pathway, including E1, E2, E3, and the proteasome itself
papertitle: 'Interplay between proteasome inhibitors and NF-κB pathway in leukemia
  and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors'
reftext: Mahdi Pakjoo, et al. Cell Commun Signal. 2024;22(NA).
year: '2024'
doi: 10.1186/s12964-023-01433-5
journal_title: 'Cell Communication and Signaling : CCS'
journal_nlm_ta: Cell Commun Signal
publisher_name: BioMed Central
keywords: Proteasome | Proteasome inhibitors | NF-κB, leukemia | Lymphoma
automl_pathway: 0.5833542
figid_alias: PMC10851565__F2
figtype: Figure
redirect_from: /figures/PMC10851565__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10851565__12964_2023_1433_Fig2_HTML.html
  '@type': Dataset
  description: Overview on agents targeting different parts of proteasome-mediated
    degradation pathway, including E1, E2, E3, and the proteasome itself
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Bortezomib
  - Carfilzomib
  - Ixazomib
  - Delanzomib
  - Marizomib
  - Protein
---
